Cargando…
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo
Flexible heteroarotinoids (Flex-Hets) compounds regulate growth, differentiation and apoptosis in cancer cells. The hypothesis of this study was that the lead Flex-Het, SHetA2, inhibits angiogenesis by blocking cytokine release from cancer cells. SHetA2 altered secretion of thrombospondin-4 (TSP-4),...
Autores principales: | Myers, Tashanna, Chengedza, Shylet, Lightfoot, Stan, Pan, Yanfang, Dedmond, Daynelle, Cole, Lauren, Tang, Yuhong, Benbrook, Doris M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701494/ https://www.ncbi.nlm.nih.gov/pubmed/18802666 http://dx.doi.org/10.1007/s10637-008-9175-7 |
Ejemplares similares
-
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice
por: Benbrook, Doris M., et al.
Publicado: (2017) -
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022) -
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2013) -
Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021) -
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018)